drugset / Trial / NCT06144086
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
Phase 2
Completed
5 enrolled
Kiminori Kimura, MD
Japan Agency for Medical Research and Development · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.
Timeline
- Start
- 2024-05-08
- Primary completion
- 2025-03-27
- Completion
- 2025-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRI-724 | Small molecule | 280 mg/m2 | Intravenous |